Loading…
Blood ACE2 Protein Level Correlates with COVID-19 Severity
ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical reco...
Saved in:
Published in: | International journal of molecular sciences 2023-09, Vol.24 (18), p.13957 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3 |
container_end_page | |
container_issue | 18 |
container_start_page | 13957 |
container_title | International journal of molecular sciences |
container_volume | 24 |
creator | Shevchuk, Oksana Pak, Anastasia Palii, Svitlana Ivankiv, Yana Kozak, Kateryna Korda, Mykhaylo Vari, Sandor G |
description | ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p < 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels. |
doi_str_mv | 10.3390/ijms241813957 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10530872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A771803850</galeid><sourcerecordid>A771803850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</originalsourceid><addsrcrecordid>eNptkctLxDAQxosouK4evRe8eKnm0aSJF1nra2FBwcc1tOnUzdI2mrSK_73RXdQVmUOGfL_5JpOJon2MjiiV6NgsWk9SLDCVLNuIRjglJEGIZ5u_8u1ox_sFQoQSJkfRyVljbRVP8gsS3zrbg-niGbxCE-fWOWiKHnz8Zvp5nN88Ts8TLOO7IDvTv-9GW3XReNhbnePo4fLiPr9OZjdX03wyS3TKUZ8wJlMiEEYF5yAzKEXKOGZQ1hlojDjXIrye1wSTqiaaYloKQatKSJ5KToGOo9Ol7_NQtlBp6HpXNOrZmbZw78oWRq0rnZmrJ_uqMGIUiYwEh8OVg7MvA_hetcZraJqiAzt4RUSGwqdhwQJ68Add2MF1Yb5AcUkFIQz9UE9FA8p0tQ2N9aepmmQZFoiKL-roHypEBa3RtoPahPu1gmRZoJ313kH9PSRG6nPFam3F9AOrEZUn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2869382250</pqid></control><display><type>article</type><title>Blood ACE2 Protein Level Correlates with COVID-19 Severity</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Shevchuk, Oksana ; Pak, Anastasia ; Palii, Svitlana ; Ivankiv, Yana ; Kozak, Kateryna ; Korda, Mykhaylo ; Vari, Sandor G</creator><creatorcontrib>Shevchuk, Oksana ; Pak, Anastasia ; Palii, Svitlana ; Ivankiv, Yana ; Kozak, Kateryna ; Korda, Mykhaylo ; Vari, Sandor G</creatorcontrib><description>ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p < 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms241813957</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Biological products ; Blood pressure ; Blood proteins ; Body mass index ; Comorbidity ; COVID-19 ; Development and progression ; Diabetes ; Enzyme-linked immunosorbent assay ; Enzymes ; Hospitalization ; Hypertension ; Infections ; Lung diseases ; Medical personnel ; Medical records ; Obesity ; Overweight ; Pandemics ; Proteins ; Respiratory diseases ; Risk factors ; Severe acute respiratory syndrome coronavirus 2 ; Viruses</subject><ispartof>International journal of molecular sciences, 2023-09, Vol.24 (18), p.13957</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</citedby><cites>FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</cites><orcidid>0000-0003-2473-6381 ; 0000-0002-5328-4647 ; 0000-0003-3305-6265 ; 0000-0002-6066-5165</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2869382250/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2869382250?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,38493,43871,44566,53766,53768,74155,74869</link.rule.ids></links><search><creatorcontrib>Shevchuk, Oksana</creatorcontrib><creatorcontrib>Pak, Anastasia</creatorcontrib><creatorcontrib>Palii, Svitlana</creatorcontrib><creatorcontrib>Ivankiv, Yana</creatorcontrib><creatorcontrib>Kozak, Kateryna</creatorcontrib><creatorcontrib>Korda, Mykhaylo</creatorcontrib><creatorcontrib>Vari, Sandor G</creatorcontrib><title>Blood ACE2 Protein Level Correlates with COVID-19 Severity</title><title>International journal of molecular sciences</title><description>ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p < 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.</description><subject>Biological products</subject><subject>Blood pressure</subject><subject>Blood proteins</subject><subject>Body mass index</subject><subject>Comorbidity</subject><subject>COVID-19</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Hospitalization</subject><subject>Hypertension</subject><subject>Infections</subject><subject>Lung diseases</subject><subject>Medical personnel</subject><subject>Medical records</subject><subject>Obesity</subject><subject>Overweight</subject><subject>Pandemics</subject><subject>Proteins</subject><subject>Respiratory diseases</subject><subject>Risk factors</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viruses</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNptkctLxDAQxosouK4evRe8eKnm0aSJF1nra2FBwcc1tOnUzdI2mrSK_73RXdQVmUOGfL_5JpOJon2MjiiV6NgsWk9SLDCVLNuIRjglJEGIZ5u_8u1ox_sFQoQSJkfRyVljbRVP8gsS3zrbg-niGbxCE-fWOWiKHnz8Zvp5nN88Ts8TLOO7IDvTv-9GW3XReNhbnePo4fLiPr9OZjdX03wyS3TKUZ8wJlMiEEYF5yAzKEXKOGZQ1hlojDjXIrye1wSTqiaaYloKQatKSJ5KToGOo9Ol7_NQtlBp6HpXNOrZmbZw78oWRq0rnZmrJ_uqMGIUiYwEh8OVg7MvA_hetcZraJqiAzt4RUSGwqdhwQJ68Add2MF1Yb5AcUkFIQz9UE9FA8p0tQ2N9aepmmQZFoiKL-roHypEBa3RtoPahPu1gmRZoJ313kH9PSRG6nPFam3F9AOrEZUn</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Shevchuk, Oksana</creator><creator>Pak, Anastasia</creator><creator>Palii, Svitlana</creator><creator>Ivankiv, Yana</creator><creator>Kozak, Kateryna</creator><creator>Korda, Mykhaylo</creator><creator>Vari, Sandor G</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2473-6381</orcidid><orcidid>https://orcid.org/0000-0002-5328-4647</orcidid><orcidid>https://orcid.org/0000-0003-3305-6265</orcidid><orcidid>https://orcid.org/0000-0002-6066-5165</orcidid></search><sort><creationdate>20230901</creationdate><title>Blood ACE2 Protein Level Correlates with COVID-19 Severity</title><author>Shevchuk, Oksana ; Pak, Anastasia ; Palii, Svitlana ; Ivankiv, Yana ; Kozak, Kateryna ; Korda, Mykhaylo ; Vari, Sandor G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biological products</topic><topic>Blood pressure</topic><topic>Blood proteins</topic><topic>Body mass index</topic><topic>Comorbidity</topic><topic>COVID-19</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Hospitalization</topic><topic>Hypertension</topic><topic>Infections</topic><topic>Lung diseases</topic><topic>Medical personnel</topic><topic>Medical records</topic><topic>Obesity</topic><topic>Overweight</topic><topic>Pandemics</topic><topic>Proteins</topic><topic>Respiratory diseases</topic><topic>Risk factors</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shevchuk, Oksana</creatorcontrib><creatorcontrib>Pak, Anastasia</creatorcontrib><creatorcontrib>Palii, Svitlana</creatorcontrib><creatorcontrib>Ivankiv, Yana</creatorcontrib><creatorcontrib>Kozak, Kateryna</creatorcontrib><creatorcontrib>Korda, Mykhaylo</creatorcontrib><creatorcontrib>Vari, Sandor G</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shevchuk, Oksana</au><au>Pak, Anastasia</au><au>Palii, Svitlana</au><au>Ivankiv, Yana</au><au>Kozak, Kateryna</au><au>Korda, Mykhaylo</au><au>Vari, Sandor G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood ACE2 Protein Level Correlates with COVID-19 Severity</atitle><jtitle>International journal of molecular sciences</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>24</volume><issue>18</issue><spage>13957</spage><pages>13957-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p < 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/ijms241813957</doi><orcidid>https://orcid.org/0000-0003-2473-6381</orcidid><orcidid>https://orcid.org/0000-0002-5328-4647</orcidid><orcidid>https://orcid.org/0000-0003-3305-6265</orcidid><orcidid>https://orcid.org/0000-0002-6066-5165</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2023-09, Vol.24 (18), p.13957 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10530872 |
source | Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
subjects | Biological products Blood pressure Blood proteins Body mass index Comorbidity COVID-19 Development and progression Diabetes Enzyme-linked immunosorbent assay Enzymes Hospitalization Hypertension Infections Lung diseases Medical personnel Medical records Obesity Overweight Pandemics Proteins Respiratory diseases Risk factors Severe acute respiratory syndrome coronavirus 2 Viruses |
title | Blood ACE2 Protein Level Correlates with COVID-19 Severity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A48%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20ACE2%20Protein%20Level%20Correlates%20with%20COVID-19%20Severity&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Shevchuk,%20Oksana&rft.date=2023-09-01&rft.volume=24&rft.issue=18&rft.spage=13957&rft.pages=13957-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms241813957&rft_dat=%3Cgale_pubme%3EA771803850%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2869382250&rft_id=info:pmid/&rft_galeid=A771803850&rfr_iscdi=true |